"Does sermorelin work?" has two honest answers. It works on growth hormone: give it, and the pituitary releases more [6]. It was approved for growth-hormone-deficient children because it made them grow faster [5]. Whether it works for what adults buy it for (less fat, more muscle, more energy, slower aging) is a separate question. One six-week study of 11 men found no change in body composition [6].
Short answer: it works on growth hormone, not proven on the goals it's sold for
Sermorelin is a copy of the first 29 amino acids of the body's growth-hormone-releasing hormone. Its effect on growth hormone is well documented. Its effect on adult outcomes isn't. The table below grades each common claim by selected relevant human evidence and its limits.
| Claim | Selected human evidence | People studied | Result | Strength of evidence |
|---|---|---|---|---|
| Raises growth hormone | Vittone 1997 [6] | 11 older men | Yes, night-time release rose | Moderate (consistent, but no control group) |
| Helps GH-deficient children grow | Thorner 1996 [5] | 110 children | Yes, growth speed roughly doubled at 6 months | Moderate (open-label; the use it was approved for) |
| Adult fat distribution | Koutkia Geref trial [1] | 31 men with HIV lipodystrophy | Secondary trunk-fat change favored Geref; total fat unchanged, VAT difference nonsignificant | Small disease-specific trial; not general wellness proof |
| Adult lean mass and strength | Koutkia and Vittone [1] [6] | 31 men with HIV; 11 older healthy men | Geref HIV trial: secondary DXA lean mass increased. Older-men pilot: no DXA change, selected strength tests improved | Limited, population-specific; lean mass is not strength |
| IGF-I in adults | Corpas, Vittone and Khorram analog [4] [6] [7] | 10; 11; 19 | Response differed by molecule and regimen; Corpas and the analog increased IGF-I, Vittone did not | Small hormone studies |
| Sleep, energy and healthy aging | Acute related-GHRH sleep experiments [2] [3] | 10 men; 23 younger/older men | Sleep findings differed by protocol; no established long-term commercial sermorelin wellness benefit | Indirect, short and route-specific |
What sermorelin was approved to do, and did
In 110 children with untreated growth-hormone deficiency, once-daily sermorelin raised height velocity from 1.6 inches (4.1 cm) a year to 3.1 inches (8.0 cm) a year at six months and 2.8 inches (7.2 cm) a year at 12 months [5]. At six months, 74% were judged good responders. The study was open-label with no control group, and 86 of the 110 children were in the efficacy analysis.
That record supported the old Geref approval. It also has a ceiling. In a 1993 randomized study of 60 children with the same condition, growth on growth hormone itself was clearly faster than on sermorelin over six months: 5.7 inches (14.6 cm) a year against 3.6 to 3.7 inches (9.2 to 9.3 cm) [9].
Selected adult evidence: different regimens, limited outcomes
In 11 healthy men aged 64 to 76 with low IGF-1, six weeks of nightly sermorelin did not change IGF-1, weight, BMI, waist-to-hip ratio, or DEXA measures of muscle and fat [6]. It did raise night-time growth hormone. Two of six strength measures (upright row and shoulder press) and one endurance test improved.
Eleven people, six weeks and no placebo group make this a pilot study. It can't show that sermorelin builds muscle or burns fat, and it found no sign that it does. The authors themselves called for a better regimen to be tested. The adult-study comparison explains why other short protocols reported different IGF-I responses.
A close cousin raised IGF-1 in older adults, with mixed body results
A one-amino-acid analog, [Nle27]GHRH(1-29), was tested in 19 adults aged 55 to 71 (10 women, 9 men). After four weeks of placebo, they took it nightly for 16 weeks. Growth hormone and IGF-1 rose, with IGF-1 up 28% [7].
Lean body mass rose in the men only. Body fat, bone density and weight didn't change in either sex, and sleep quality was unchanged [8]. Skin thickness increased in both. This was not sermorelin, and it is still a 19-person study.
Koutkia’s 12-week randomized trial used Geref in 31 men with HIV lipodystrophy. IGF-I was primary; secondary DXA changes favored Geref: lean mass +2.0 lb (+0.9 kg) versus −0.7 lb (−0.3 kg) (P=.04), trunk fat −0.9 lb (−0.4 kg) versus +0.4 lb (+0.2 kg) (P=.03). Total fat was unchanged; visceral-fat difference missed significance (P=.07). This is disease-specific evidence [1].
Corpas and colleagues studied ten older men through two 14-day courses of GHRH(1-29), in randomized dose order, with nine younger men providing a baseline comparison. The higher regimen increased growth-hormone and IGF-I measures; fasting glucose, urinary C-peptide, blood pressure and routine chemistry were unchanged [4]. This is another adult exposure study, not proof of improved body composition, long-term safety or a schedule for current compounded products.
The broader GHRH sleep literature also prevents a blanket claim that sleep was never studied. Kern and colleagues found no sleep change during an overnight GHRH infusion experiment in ten men [2]. Perras and colleagues used intranasal GHRH in a crossover study of twelve younger and eleven older men and reported increases in REM and slow-wave sleep [3]. These acute, route-specific experiments do not establish the long-term benefits of commercially offered compounded sermorelin or a preferred injection timetable.
Why "raises growth hormone" isn't the same as "works"
A higher growth-hormone level is a lab result. Whether it becomes less fat, more muscle or better sleep has to be tested directly. A controlled Geref trial exists in HIV lipodystrophy, but that specific population does not establish general wellness effects.
Compare tesamorelin, another growth-hormone-releasing hormone analog. In a 412-person randomized trial it cut belly fat 15.2%, against a 5.0% rise on placebo [10]. That result was in people with HIV-associated lipodystrophy, for one approved use, and it says nothing about sermorelin. The two are compared on tesamorelin vs sermorelin, and tesamorelin has its own status page.
What it would take to show sermorelin works in adults
A convincing answer would need a randomized trial with a placebo group, a defined product and dose, outcomes chosen in advance (body fat, muscle, function, quality of life) and at least several months of follow-up. The small Geref HIV trial addresses a different population and has biomarker rather than body-composition primary outcomes. Trials designed for broad wellness goals are still needed.
| Study | Who | People | Length | Design | Main result |
|---|---|---|---|---|---|
| Thorner 1996 [5] | GH-deficient children | 110 | Up to 1 year | Open-label, no control | Height velocity 1.6 to 3.1 in/yr (4.1 to 8.0 cm/yr) at 6 months |
| Chen 1993 [9] | GH-deficient children | 60 | 6 months | Randomized vs growth hormone | Growth hormone grew children faster |
| Vittone 1997 [6] | Healthy men 64 to 76 | 11 | 6 weeks | Before and after, no control | GH up; IGF-1, fat, muscle, weight unchanged |
| Khorram 1997 (analog) [8] | Adults 55 to 71 | 19 | 16 weeks | Single-blind placebo lead-in | IGF-1 up 28%; lean mass up in men only |
| Sigalos 2017 [11] | Men on testosterone therapy | 14 | About 4 months on average | Chart review; sermorelin plus two other peptides | IGF-1 rose; sermorelin's own share unknown |
| Koutkia 2004 [1] | Men with HIV lipodystrophy | 31 | 12 weeks | Randomized placebo-controlled Geref | Primary IGF-I increased; secondary DXA changes, total fat unchanged |
Is sermorelin worth it? Know what you'd be paying for
A price does not establish a benefit. Current offers differ by form, term and billing cycle; the sermorelin hub’s selected offer table separates printed billing terms from monthly comparisons. The evidence supports hormone responses under studied protocols, with some disease-specific secondary body-composition findings. It does not establish routine energy, appearance or healthy-aging benefits from current compounded products.
- Ask whether they'll check IGF-1 before you start and during treatment.
- Ask what result would make them stop it.
- Ask which pharmacy makes it, and whether it is a 503A or a 503B pharmacy.
- Ask why a particular schedule is recommended; the studies used different protocols, covered in when to take sermorelin.
Does it work as tablets or nasal spray? The evidence is weaker still
Every study above used injections under the skin. Tablets, lozenges and nasal sprays have even less behind them, as covered in do sermorelin tablets work.
Safety in one paragraph: small, short studies and no current label
The studies reported sermorelin as well tolerated, but they were small and short [5] [6]. In the 1993 pediatric trial, 39 of 40 children on it developed antibodies to it, which faded after treatment stopped [9]. There is no current FDA label with an official safety section, because the approvals were withdrawn in 2009 [12]. More on is sermorelin safe and is sermorelin FDA approved.